T Cell News and Research

Latest T Cell News and Research

Scripps scientists to develop new generation of broad spectrum anti-cancer therapeutics

A pair of Scripps Research Institute scientists, one a cancer biologist and the other a chemist, has been awarded $3.85 million from the National Institutes of Health (NIH) to develop a new generation of broad spectrum anti-cancer therapeutics, including breast cancer and lymphoma.

6 Mar 2012

New AD marker can predict mental decline

A new marker of Alzheimer's disease can predict how rapidly a patient's memory and other mental abilities will decline after the disorder is diagnosed, researchers at Washington University School of Medicine in St. Louis have found.

6 Mar 2012

Penn-led team develops universal approach to personalized cancer therapy based on T cells

Researchers from the Perelman School of Medicine at the University of Pennsylvania report this month in Cancer Research a universal approach to personalized cancer therapy based on T cells. It is the first time a system for making an adaptable, engineered T-cell to attack specific tumor types has been proposed, depending on which abnormal proteins, called antigens, are expressed by individual patients' tumor cells.

6 Mar 2012

T-cells can develop in human tonsils

A new study provides evidence that a critical type of immune cell can develop in human tonsils. The cells, called T lymphocytes, or T cells, have been thought to develop only in the thymus, an organ of the immune system that sits on the heart.

6 Mar 2012

Scientists identify novel protein expressed by breast cancer cells

A team of scientists at the University of California, San Diego Moores Cancer Center has identified a novel protein expressed by breast cancer cells - but not normal adult tissues - that could provide a new target for future anti-cancer drugs and treatments.

6 Mar 2012

Scientists to investigate biochemical switch: P2X1 receptor

Scientists investigating a 'biochemical switch' linked to strokes and heart disease claim to have made an advance in understanding how it is 'turned on'.

6 Mar 2012

$Millennium commences MLN8237 phase 3 trial in relapsed or refractory PTCL$

Millennium commences MLN8237 phase 3 trial in relapsed or refractory PTCL

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the initiation of an international phase 3 clinical trial evaluating MLN8237 in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), an aggressive form of lymphoma.

5 Mar 2012

Scientists identify gene that causes adult-onset primary cervical dystonia

Researchers have identified a gene that causes adult-onset primary cervical dystonia, an often-painful condition in which patients' necks twist involuntarily.

5 Mar 2012

MicroRNAs key to memory and learning process

Studying tiny bits of genetic material that control protein formation in the brain, Johns Hopkins scientists say they have new clues to how memories are made and how drugs might someday be used to stop disruptions in the process that lead to mental illness and brain wasting diseases.

5 Mar 2012

Certain microRNAs key to controlling actions of BDNF, linked to brain cell survival

5 Mar 2012

Cell-based test to discover molecules to treat ER-positive breast cancer

Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer.

5 Mar 2012

Nuvilex overcomes fundamental challenges faced in stem cell therapy

Nuvilex, Inc., an emerging biotechnology provider of cell and gene therapy solutions, released information today about the company's cell encapsulation technology and the breakthrough in stem cell research which overcomes specific fundamental challenges faced in stem cell therapy—host rejection and migration of implanted cells away from the target site.

5 Mar 2012

Inovio's SynCon vaccine for HPV types 6 and 11 induces CD8+ T cells in mice

Inovio Pharmaceuticals, Inc. announced today that its SynCon therapeutic vaccine for human papillomavirus (HPV) types 6 and 11, which are associated with head & neck cancers and genital warts, among other conditions, induced strong antigen-specific CD8+ T cells in mice.

5 Mar 2012

IDS, AADA disappointed in postponement of vote by Idaho on indoor tanning bed legislation

The Idaho Dermatology Society (IDS) and the American Academy of Dermatology Association (AADA) are disappointed in the postponement of the vote by the Idaho House of Representatives on House Bill 486, which would ban the use of indoor tanning beds by minors under the age of 18.

5 Mar 2012

Bovine collagen can enhance gum healing

Receding gums often result in tooth sensitivity and can lead to decay of the root and persistent inflammation of the gum. New research published in BioMed Central's open access journal Head & Face Medicine demonstrates that a novel method using bovine collagen is able to enhance gum healing. This resulted in thicker margins around the tooth and, in over half the cases, complete coverage of exposed roots.

5 Mar 2012

Scientists discover how to enhance production of hepatocytes to repair damaged liver tissue

Scientists have shed light on how the liver repairs itself with research that could help develop drugs to treat liver disease.

4 Mar 2012

Novel partnership could transform breast cancer diagnosis

An innovative University of Sydney research partnership with private enterprise could see a radical change in how breast cancer is diagnosed, with the possibility to improve detection rates.

4 Mar 2012

New APS policy requires reporting of sex and gender in experimental studies

The American Physiology Society (APS) has announced a new policy requiring the reporting of the sex of experimental animals and the sex or gender of humans used in studies submitted for publication in any of the organization's 13 peer-reviewed journals.

3 Mar 2012

Rigosertib drug shows promise against advanced pancreatic cancer

The American Cancer Society estimates that 44,000 new cases of pancreatic cancer will be diagnosed this year and that 37,000 people will die from the disease. These are not strong odds. A new drug, rigosertib, allows pancreatic cancer cells to rush through replication - and then stops them cold, killing them in in the middle of a step called M phase. Healthy cells that don't rush are unharmed.

3 Mar 2012

R-loop formation may drive under-methylation and autoimmunity

Researchers at the University of California, Davis, have figured out how the human body keeps essential genes switched "on" and silences the vast stretches of genetic repeats and "junk" DNA.

3 Mar 2012